Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44)

Browse all the diagnosis codes used for poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (t44). For easy navigation, the diagnosis codes are sorted in alphabetical order and grouped by sections. Each section is clearly marked with its description, and the corresponding three-digit code range. This format makes it simple to browse diagnosis codes in this chapter or section and find what you're looking for. We've also added green checkmark icons to label billable codes, and red warning icons for non-billable ones. This makes it easy to identify which codes can be billed.

Clinical Information

Acebutolol - A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.

Acetylcholine - A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system.

Acetylcholine Release Inhibitors - Compounds that block release of the neurotransmitter ACETYLCHOLINE.

Acetylcholinesterase - An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7.

Alprenolol - One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.

Arecoline - An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.

Arylsulfotransferase - A sulfotransferase that catalyzes the sulfation of a phenol in the presence of 3'-phosphoadenylylsulfate as sulfate donor to yield an aryl sulfate and adenosine 3',5'-bisphosphate. A number of aromatic compounds can act as acceptors; however, organic hydroxylamines are not substrates. Sulfate conjugation by this enzyme is a major pathway for the biotransformation of phenolic and catechol drugs as well as neurotransmitters. EC 2.8.2.1.

Atenolol - A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.

Atropine - An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine.

Atropine Derivatives - Analogs and derivatives of atropine.

Beclomethasone - An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of ASTHMA.

Benactyzine - A centrally acting muscarinic antagonist. Benactyzine has been used in the treatment of depression and is used in research to investigate the role of cholinergic systems on behavior.

Benztropine - A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Betaxolol - A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

Bethanechol - A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.

Bethanechol Compounds - Quaternary ammonium compounds that include BETHANECHOL.

Biperiden - A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

Bisoprolol - A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Budesonide - A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Budesonide, Formoterol Fumarate Drug Combination - A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Bupranolol - An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.

Butylscopolammonium Bromide - Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.

Carbachol - A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.

Carteolol - A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

Celiprolol - A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.

Cholinergic Agents - Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage.

Cholinergic Agonists - Drugs that bind to and activate cholinergic receptors.

Cholinergic Antagonists - Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists.

Cholinesterase Inhibitors - Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Cyclopentolate - A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

Dexetimide - A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

Dicyclomine - A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.

Dobutamine - A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.

Dopamine - One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.

Dopamine Agents - Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Dopamine Agonists - Drugs that bind to and activate dopamine receptors.

Dopamine and cAMP-Regulated Phosphoprotein 32 - A phosphoprotein that was initially identified as a major target of DOPAMINE activated ADENYLYL CYCLASE in the CORPUS STRIATUM. It regulates the activities of PROTEIN PHOSPHATASE-1 and PROTEIN KINASE A, and it is a key mediator of the biochemical, electrophysiological, transcriptional, and behavioral effects of DOPAMINE.

Dopamine Antagonists - Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Dopamine beta-Hydroxylase - One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.

Dopamine D2 Receptor Antagonists - Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS.

Dopamine Plasma Membrane Transport Proteins - Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS.

Dopamine Uptake Inhibitors - Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Dopaminergic Imaging - Functional brain imaging techniques that utilize various RADIONUCLIDE TRACERS that bind to different targets in the SYNAPSES of DOPAMINERGIC NEURONS.

Dopaminergic Neurons - Neurons whose primary neurotransmitter is DOPAMINE.

Doxazosin - A prazosin-related compound that is a selective alpha-1-adrenergic blocker.

Dyphylline - A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.

Echocardiography, Stress - A method of recording heart motion and internal structures by combining ultrasonic imaging with exercise testing (EXERCISE TEST) or pharmacologic stress.

Edrophonium - A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.

Ephedra - A plant genus of the family Ephedraceae, order Ephedrales, class Gnetopsida, division Gnetophyta.

Ephedra sinica - A plant species of the family Ephedraceae, order Ephedrales, class Gnetopsida, division Gnetophyta. It is a source of EPHEDRINE and other alkaloids.

Ephedrine - A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.

Epinephrine - The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.

Etilefrine - A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.

Flavoxate - A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.

Galantamine - A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.

Gefarnate - A water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.

Glycopyrrolate - A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.

Hyoscyamine - The 3(S)-endo isomer of atropine.

Hyoscyamus - A plant genus of the family SOLANACEAE which contains TROPANES.

Indoramin - An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.

Isoetharine - Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.

Isoflurophate - A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.

Labetalol - A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.

Mecamylamine - A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Mephentermine - A sympathomimetic agent with specificity for alpha-1 adrenergic receptors. It is used to maintain BLOOD PRESSURE in hypotensive states such as following SPINAL ANESTHESIA.

Metaraminol - A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.

Methantheline - A quaternary ammonium compound that acts as an antimuscarinic agent. It has been used in the treatment of PEPTIC ULCER, in gastrointestinal disorders associated with smooth muscle spasm, and in the management of urinary incontinence, and may also be used for the treatment of HYPERHIDROSIS.

Methoxamine - An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.

Metoprolol - A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Nadolol - A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.

N-Methylscopolamine - A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

Norepinephrine - Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic.

Norepinephrine Plasma Membrane Transport Proteins - Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of noradrenergic neurons. They remove NOREPINEPHRINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. The norepinephrine transporter regulates signal amplitude and duration at noradrenergic synapses and is the target of ADRENERGIC UPTAKE INHIBITORS.

Oxprenolol - A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Papaverine - An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.

Parasympathomimetics - Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Pempidine - A nicotinic antagonist most commonly used as an experimental tool. It has been used as a ganglionic blocker in the treatment of hypertension but has largely been supplanted for that purpose by more specific drugs.

Penbutolol - A nonselective beta-blocker used as an antihypertensive and an antianginal agent.

Phenylephrine - An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.

Phenylethanolamine N-Methyltransferase - A methyltransferase that catalyzes the reaction of S-adenosyl-L-methionine and phenylethanolamine to yield S-adenosyl-L-homocysteine and N-methylphenylethanolamine. It can act on various phenylethanolamines and converts norepinephrine into epinephrine. (From Enzyme Nomenclature, 1992) EC 2.1.1.28.

Phenylpropanolamine - A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.

Pilocarpine - A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Pindolol - A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)

Practolol - A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.

Prazosin - A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.

Prenalterol - A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME.

Procaterol - A long-acting beta-2-adrenergic receptor agonist.

Procyclidine - A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.

Propantheline - A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

Propranolol - A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.

Pseudoephedrine - A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.

Pyridostigmine Bromide - A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.

Racepinephrine - A racemic mixture of d-epinephrine and l-epinephrine.

Receptors, Adrenergic - Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction.

Receptors, Cholinergic - Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.

Receptors, Dopamine - Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.

Receptors, Dopamine D1 - A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.

Receptors, Dopamine D2 - A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.

Receptors, Dopamine D3 - A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain.

Receptors, Dopamine D4 - A subtype of dopamine D2 receptors that has high affinity for the antipsychotic CLOZAPINE.

Receptors, Dopamine D5 - A subtype of dopamine D1 receptors that has higher affinity for DOPAMINE and differentially couples to GTP-BINDING PROTEINS.

Receptors, Muscarinic - One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology.

Receptors, Nicotinic - One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.

Ritodrine - An adrenergic beta-2 agonist used to control PREMATURE LABOR.

Scopolamine - An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic.

Scopolamine Derivatives - Analogs or derivatives of scopolamine.

Sotalol - An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.

Tacrine - A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.

Tamsulosin - A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA.

Timolol - A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Tolperisone - A centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1211)

Trihexyphenidyl - One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Trimebutine - Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.

Trimethaphan - A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.

Tropicamide - One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.

Vesicular Acetylcholine Transport Proteins - Vesicular amine transporter proteins that transport the neurotransmitter ACETYLCHOLINE into small SECRETORY VESICLES. Proteins of this family contain 12 transmembrane domains and exchange vesicular PROTONS for cytoplasmic acetylcholine.

Xamoterol - A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.

Instructional Notations

7th Character Note

Certain ICD-10-CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.

  • The appropriate 7th character is to be added to each code from category T44

7th Character

Indicates that a seventh character is to be assigned to codes in a subcategory.

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela
  • Injury, poisoning and certain other consequences of external causes (S00–T88)

    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50)

        • Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44)

        • T44 Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system
        • T44.0 Poisoning by, adverse effect of and underdosing of anticholinesterase agents
        • T44.0X Poisoning by, adverse effect of and underdosing of anticholinesterase agents
        • T44.0X1 Poisoning by anticholinesterase agents, accidental (unintentional)
        • T44.0X1A Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter
        • T44.0X1D Poisoning by anticholinesterase agents, accidental (unintentional), subsequent encounter
        • T44.0X1S Poisoning by anticholinesterase agents, accidental (unintentional), sequela
        • T44.0X2 Poisoning by anticholinesterase agents, intentional self-harm
        • T44.0X2A Poisoning by anticholinesterase agents, intentional self-harm, initial encounter
        • T44.0X2D Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter
        • T44.0X2S Poisoning by anticholinesterase agents, intentional self-harm, sequela
        • T44.0X3 Poisoning by anticholinesterase agents, assault
        • T44.0X3A Poisoning by anticholinesterase agents, assault, initial encounter
        • T44.0X3D Poisoning by anticholinesterase agents, assault, subsequent encounter
        • T44.0X3S Poisoning by anticholinesterase agents, assault, sequela
        • T44.0X4 Poisoning by anticholinesterase agents, undetermined
        • T44.0X4A Poisoning by anticholinesterase agents, undetermined, initial encounter
        • T44.0X4D Poisoning by anticholinesterase agents, undetermined, subsequent encounter
        • T44.0X4S Poisoning by anticholinesterase agents, undetermined, sequela
        • T44.0X5 Adverse effect of anticholinesterase agents
        • T44.0X5A Adverse effect of anticholinesterase agents, initial encounter
        • T44.0X5D Adverse effect of anticholinesterase agents, subsequent encounter
        • T44.0X5S Adverse effect of anticholinesterase agents, sequela
        • T44.0X6 Underdosing of anticholinesterase agents
        • T44.0X6A Underdosing of anticholinesterase agents, initial encounter
        • T44.0X6D Underdosing of anticholinesterase agents, subsequent encounter
        • T44.0X6S Underdosing of anticholinesterase agents, sequela
        • T44.1 Poisoning by, adverse effect of and underdosing of other parasympathomimetics [cholinergics]
        • T44.1X Poisoning by, adverse effect of and underdosing of other parasympathomimetics [cholinergics]
        • T44.1X1 Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional)
        • T44.1X1A Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional), initial encounter
        • T44.1X1D Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional), subsequent encounter
        • T44.1X1S Poisoning by other parasympathomimetics [cholinergics], accidental (unintentional), sequela
        • T44.1X2 Poisoning by other parasympathomimetics [cholinergics], intentional self-harm
        • T44.1X2A Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter
        • T44.1X2D Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter
        • T44.1X2S Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela
        • T44.1X3 Poisoning by other parasympathomimetics [cholinergics], assault
        • T44.1X3A Poisoning by other parasympathomimetics [cholinergics], assault, initial encounter
        • T44.1X3D Poisoning by other parasympathomimetics [cholinergics], assault, subsequent encounter
        • T44.1X3S Poisoning by other parasympathomimetics [cholinergics], assault, sequela
        • T44.1X4 Poisoning by other parasympathomimetics [cholinergics], undetermined
        • T44.1X4A Poisoning by other parasympathomimetics [cholinergics], undetermined, initial encounter
        • T44.1X4D Poisoning by other parasympathomimetics [cholinergics], undetermined, subsequent encounter
        • T44.1X4S Poisoning by other parasympathomimetics [cholinergics], undetermined, sequela
        • T44.1X5 Adverse effect of other parasympathomimetics [cholinergics]
        • T44.1X5A Adverse effect of other parasympathomimetics [cholinergics], initial encounter
        • T44.1X5D Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter
        • T44.1X5S Adverse effect of other parasympathomimetics [cholinergics], sequela
        • T44.1X6 Underdosing of other parasympathomimetics [cholinergics]
        • T44.1X6A Underdosing of other parasympathomimetics [cholinergics], initial encounter
        • T44.1X6D Underdosing of other parasympathomimetics [cholinergics], subsequent encounter
        • T44.1X6S Underdosing of other parasympathomimetics [cholinergics], sequela
        • T44.2 Poisoning by, adverse effect of and underdosing of ganglionic blocking drugs
        • T44.2X Poisoning by, adverse effect of and underdosing of ganglionic blocking drugs
        • T44.2X1 Poisoning by ganglionic blocking drugs, accidental (unintentional)
        • T44.2X1A Poisoning by ganglionic blocking drugs, accidental (unintentional), initial encounter
        • T44.2X1D Poisoning by ganglionic blocking drugs, accidental (unintentional), subsequent encounter
        • T44.2X1S Poisoning by ganglionic blocking drugs, accidental (unintentional), sequela
        • T44.2X2 Poisoning by ganglionic blocking drugs, intentional self-harm
        • T44.2X2A Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter
        • T44.2X2D Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter
        • T44.2X2S Poisoning by ganglionic blocking drugs, intentional self-harm, sequela
        • T44.2X3 Poisoning by ganglionic blocking drugs, assault
        • T44.2X3A Poisoning by ganglionic blocking drugs, assault, initial encounter
        • T44.2X3D Poisoning by ganglionic blocking drugs, assault, subsequent encounter
        • T44.2X3S Poisoning by ganglionic blocking drugs, assault, sequela
        • T44.2X4 Poisoning by ganglionic blocking drugs, undetermined
        • T44.2X4A Poisoning by ganglionic blocking drugs, undetermined, initial encounter
        • T44.2X4D Poisoning by ganglionic blocking drugs, undetermined, subsequent encounter
        • T44.2X4S Poisoning by ganglionic blocking drugs, undetermined, sequela
        • T44.2X5 Adverse effect of ganglionic blocking drugs
        • T44.2X5A Adverse effect of ganglionic blocking drugs, initial encounter
        • T44.2X5D Adverse effect of ganglionic blocking drugs, subsequent encounter
        • T44.2X5S Adverse effect of ganglionic blocking drugs, sequela
        • T44.2X6 Underdosing of ganglionic blocking drugs
        • T44.2X6A Underdosing of ganglionic blocking drugs, initial encounter
        • T44.2X6D Underdosing of ganglionic blocking drugs, subsequent encounter
        • T44.2X6S Underdosing of ganglionic blocking drugs, sequela
        • T44.3 Poisoning by, adverse effect of and underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
        • T44.3X Poisoning by, adverse effect of and underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
        • T44.3X1 Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional)
        • T44.3X1A Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), initial encounter
        • T44.3X1D Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), subsequent encounter
        • T44.3X1S Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), sequela
        • T44.3X2 Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm
        • T44.3X2A Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter
        • T44.3X2D Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter
        • T44.3X2S Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela
        • T44.3X3 Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault
        • T44.3X3A Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, initial encounter
        • T44.3X3D Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, subsequent encounter
        • T44.3X3S Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, sequela
        • T44.3X4 Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined
        • T44.3X4A Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, initial encounter
        • T44.3X4D Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, subsequent encounter
        • T44.3X4S Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, sequela
        • T44.3X5 Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
        • T44.3X5A Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
        • T44.3X5D Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
        • T44.3X5S Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
        • T44.3X6 Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
        • T44.3X6A Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
        • T44.3X6D Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
        • T44.3X6S Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
        • T44.4 Poisoning by, adverse effect of and underdosing of predominantly alpha-adrenoreceptor agonists
        • T44.4X Poisoning by, adverse effect of and underdosing of predominantly alpha-adrenoreceptor agonists
        • T44.4X1 Poisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional)
        • T44.4X1A Poisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), initial encounter
        • T44.4X1D Poisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
        • T44.4X1S Poisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), sequela
        • T44.4X2 Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm
        • T44.4X2A Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter
        • T44.4X2D Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter
        • T44.4X2S Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela
        • T44.4X3 Poisoning by predominantly alpha-adrenoreceptor agonists, assault
        • T44.4X3A Poisoning by predominantly alpha-adrenoreceptor agonists, assault, initial encounter
        • T44.4X3D Poisoning by predominantly alpha-adrenoreceptor agonists, assault, subsequent encounter
        • T44.4X3S Poisoning by predominantly alpha-adrenoreceptor agonists, assault, sequela
        • T44.4X4 Poisoning by predominantly alpha-adrenoreceptor agonists, undetermined
        • T44.4X4A Poisoning by predominantly alpha-adrenoreceptor agonists, undetermined, initial encounter
        • T44.4X4D Poisoning by predominantly alpha-adrenoreceptor agonists, undetermined, subsequent encounter
        • T44.4X4S Poisoning by predominantly alpha-adrenoreceptor agonists, undetermined, sequela
        • T44.4X5 Adverse effect of predominantly alpha-adrenoreceptor agonists
        • T44.4X5A Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
        • T44.4X5D Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
        • T44.4X5S Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
        • T44.4X6 Underdosing of predominantly alpha-adrenoreceptor agonists
        • T44.4X6A Underdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
        • T44.4X6D Underdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
        • T44.4X6S Underdosing of predominantly alpha-adrenoreceptor agonists, sequela
        • T44.5 Poisoning by, adverse effect of and underdosing of predominantly beta-adrenoreceptor agonists
        • T44.5X Poisoning by, adverse effect of and underdosing of predominantly beta-adrenoreceptor agonists
        • T44.5X1 Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional)
        • T44.5X1A Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), initial encounter
        • T44.5X1D Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
        • T44.5X1S Poisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), sequela
        • T44.5X2 Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm
        • T44.5X2A Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter
        • T44.5X2D Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter
        • T44.5X2S Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela
        • T44.5X3 Poisoning by predominantly beta-adrenoreceptor agonists, assault
        • T44.5X3A Poisoning by predominantly beta-adrenoreceptor agonists, assault, initial encounter
        • T44.5X3D Poisoning by predominantly beta-adrenoreceptor agonists, assault, subsequent encounter
        • T44.5X3S Poisoning by predominantly beta-adrenoreceptor agonists, assault, sequela
        • T44.5X4 Poisoning by predominantly beta-adrenoreceptor agonists, undetermined
        • T44.5X4A Poisoning by predominantly beta-adrenoreceptor agonists, undetermined, initial encounter
        • T44.5X4D Poisoning by predominantly beta-adrenoreceptor agonists, undetermined, subsequent encounter
        • T44.5X4S Poisoning by predominantly beta-adrenoreceptor agonists, undetermined, sequela
        • T44.5X5 Adverse effect of predominantly beta-adrenoreceptor agonists
        • T44.5X5A Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
        • T44.5X5D Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
        • T44.5X5S Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
        • T44.5X6 Underdosing of predominantly beta-adrenoreceptor agonists
        • T44.5X6A Underdosing of predominantly beta-adrenoreceptor agonists, initial encounter
        • T44.5X6D Underdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
        • T44.5X6S Underdosing of predominantly beta-adrenoreceptor agonists, sequela
        • T44.6 Poisoning by, adverse effect of and underdosing of alpha-adrenoreceptor antagonists
        • T44.6X Poisoning by, adverse effect of and underdosing of alpha-adrenoreceptor antagonists
        • T44.6X1 Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional)
        • T44.6X1A Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), initial encounter
        • T44.6X1D Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
        • T44.6X1S Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), sequela
        • T44.6X2 Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm
        • T44.6X2A Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter
        • T44.6X2D Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
        • T44.6X2S Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela
        • T44.6X3 Poisoning by alpha-adrenoreceptor antagonists, assault
        • T44.6X3A Poisoning by alpha-adrenoreceptor antagonists, assault, initial encounter
        • T44.6X3D Poisoning by alpha-adrenoreceptor antagonists, assault, subsequent encounter
        • T44.6X3S Poisoning by alpha-adrenoreceptor antagonists, assault, sequela
        • T44.6X4 Poisoning by alpha-adrenoreceptor antagonists, undetermined
        • T44.6X4A Poisoning by alpha-adrenoreceptor antagonists, undetermined, initial encounter
        • T44.6X4D Poisoning by alpha-adrenoreceptor antagonists, undetermined, subsequent encounter
        • T44.6X4S Poisoning by alpha-adrenoreceptor antagonists, undetermined, sequela
        • T44.6X5 Adverse effect of alpha-adrenoreceptor antagonists
        • T44.6X5A Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
        • T44.6X5D Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
        • T44.6X5S Adverse effect of alpha-adrenoreceptor antagonists, sequela
        • T44.6X6 Underdosing of alpha-adrenoreceptor antagonists
        • T44.6X6A Underdosing of alpha-adrenoreceptor antagonists, initial encounter
        • T44.6X6D Underdosing of alpha-adrenoreceptor antagonists, subsequent encounter
        • T44.6X6S Underdosing of alpha-adrenoreceptor antagonists, sequela
        • T44.7 Poisoning by, adverse effect of and underdosing of beta-adrenoreceptor antagonists
        • T44.7X Poisoning by, adverse effect of and underdosing of beta-adrenoreceptor antagonists
        • T44.7X1 Poisoning by beta-adrenoreceptor antagonists, accidental (unintentional)
        • T44.7X1A Poisoning by beta-adrenoreceptor antagonists, accidental (unintentional), initial encounter
        • T44.7X1D Poisoning by beta-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
        • T44.7X1S Poisoning by beta-adrenoreceptor antagonists, accidental (unintentional), sequela
        • T44.7X2 Poisoning by beta-adrenoreceptor antagonists, intentional self-harm
        • T44.7X2A Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter
        • T44.7X2D Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
        • T44.7X2S Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela
        • T44.7X3 Poisoning by beta-adrenoreceptor antagonists, assault
        • T44.7X3A Poisoning by beta-adrenoreceptor antagonists, assault, initial encounter
        • T44.7X3D Poisoning by beta-adrenoreceptor antagonists, assault, subsequent encounter
        • T44.7X3S Poisoning by beta-adrenoreceptor antagonists, assault, sequela
        • T44.7X4 Poisoning by beta-adrenoreceptor antagonists, undetermined
        • T44.7X4A Poisoning by beta-adrenoreceptor antagonists, undetermined, initial encounter
        • T44.7X4D Poisoning by beta-adrenoreceptor antagonists, undetermined, subsequent encounter
        • T44.7X4S Poisoning by beta-adrenoreceptor antagonists, undetermined, sequela
        • T44.7X5 Adverse effect of beta-adrenoreceptor antagonists
        • T44.7X5A Adverse effect of beta-adrenoreceptor antagonists, initial encounter
        • T44.7X5D Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
        • T44.7X5S Adverse effect of beta-adrenoreceptor antagonists, sequela
        • T44.7X6 Underdosing of beta-adrenoreceptor antagonists
        • T44.7X6A Underdosing of beta-adrenoreceptor antagonists, initial encounter
        • T44.7X6D Underdosing of beta-adrenoreceptor antagonists, subsequent encounter
        • T44.7X6S Underdosing of beta-adrenoreceptor antagonists, sequela
        • T44.8 Poisoning by, adverse effect of and underdosing of centrally-acting and adrenergic-neuron- blocking agents
        • T44.8X Poisoning by, adverse effect of and underdosing of centrally-acting and adrenergic- neuron-blocking agents
        • T44.8X1 Poisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional)
        • T44.8X1A Poisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), initial encounter
        • T44.8X1D Poisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), subsequent encounter
        • T44.8X1S Poisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), sequela
        • T44.8X2 Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm
        • T44.8X2A Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter
        • T44.8X2D Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter
        • T44.8X2S Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela
        • T44.8X3 Poisoning by centrally-acting and adrenergic-neuron-blocking agents, assault
        • T44.8X3A Poisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, initial encounter
        • T44.8X3D Poisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, subsequent encounter
        • T44.8X3S Poisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, sequela
        • T44.8X4 Poisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined
        • T44.8X4A Poisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, initial encounter
        • T44.8X4D Poisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, subsequent encounter
        • T44.8X4S Poisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, sequela
        • T44.8X5 Adverse effect of centrally-acting and adrenergic-neuron-blocking agents
        • T44.8X5A Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
        • T44.8X5D Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
        • T44.8X5S Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
        • T44.8X6 Underdosing of centrally-acting and adrenergic-neuron-blocking agents
        • T44.8X6A Underdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
        • T44.8X6D Underdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
        • T44.8X6S Underdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
        • T44.9 Poisoning by, adverse effect of and underdosing of other and unspecified drugs primarily affecting the autonomic nervous system
        • T44.90 Poisoning by, adverse effect of and underdosing of unspecified drugs primarily affecting the autonomic nervous system
        • T44.901 Poisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional)
        • T44.901A Poisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), initial encounter
        • T44.901D Poisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
        • T44.901S Poisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), sequela
        • T44.902 Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm
        • T44.902A Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
        • T44.902D Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
        • T44.902S Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela
        • T44.903 Poisoning by unspecified drugs primarily affecting the autonomic nervous system, assault
        • T44.903A Poisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, initial encounter
        • T44.903D Poisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, subsequent encounter
        • T44.903S Poisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, sequela
        • T44.904 Poisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined
        • T44.904A Poisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, initial encounter
        • T44.904D Poisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, subsequent encounter
        • T44.904S Poisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, sequela
        • T44.905 Adverse effect of unspecified drugs primarily affecting the autonomic nervous system
        • T44.905A Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
        • T44.905D Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
        • T44.905S Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
        • T44.906 Underdosing of unspecified drugs primarily affecting the autonomic nervous system
        • T44.906A Underdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
        • T44.906D Underdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
        • T44.906S Underdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
        • T44.99 Poisoning by, adverse effect of and underdosing of other drugs primarily affecting the autonomic nervous system
        • T44.991 Poisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional)
        • T44.991A Poisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), initial encounter
        • T44.991D Poisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
        • T44.991S Poisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), sequela
        • T44.992 Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm
        • T44.992A Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
        • T44.992D Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
        • T44.992S Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela
        • T44.993 Poisoning by other drug primarily affecting the autonomic nervous system, assault
        • T44.993A Poisoning by other drug primarily affecting the autonomic nervous system, assault, initial encounter
        • T44.993D Poisoning by other drug primarily affecting the autonomic nervous system, assault, subsequent encounter
        • T44.993S Poisoning by other drug primarily affecting the autonomic nervous system, assault, sequela
        • T44.994 Poisoning by other drug primarily affecting the autonomic nervous system, undetermined
        • T44.994A Poisoning by other drug primarily affecting the autonomic nervous system, undetermined, initial encounter
        • T44.994D Poisoning by other drug primarily affecting the autonomic nervous system, undetermined, subsequent encounter
        • T44.994S Poisoning by other drug primarily affecting the autonomic nervous system, undetermined, sequela
        • T44.995 Adverse effect of other drug primarily affecting the autonomic nervous system
        • T44.995A Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
        • T44.995D Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
        • T44.995S Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
        • T44.996 Underdosing of other drug primarily affecting the autonomic nervous system
        • T44.996A Underdosing of other drug primarily affecting the autonomic nervous system, initial encounter
        • T44.996D Underdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
        • T44.996S Underdosing of other drug primarily affecting the autonomic nervous system, sequela